Vertex's Kidney Trial Win: Progress or Peril for Biotech Bulls?

Vertex Pharmaceuticals surged 4% on rare disease trial success, but investors should weigh pipeline risks against diversification hopes.

Oracle's Cloud Ascendancy: Can It Weather the AI Storm?

Oracle's Q3 earnings beat underscores its successful cloud pivot, but can it maintain momentum amid intensifying AI infrastructure demands?

---

While the Dow Panics, Tech Plays Defense: What the 800-Point Swing Really Tells Us

TSX Materials Rally Outpaces US Markets as Gold Hits Record Highs

Canadian equities outperform as materials and financials drive .GSPTSE to 33,270.65 while gold surges to $5,242/oz.